MedTrace Logo

Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies

NCT05304195 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2025-11-20

No results posted yet for this study

Summary

This research focuses on the activity of an enzymatic protein: glucocerebrosidase, in dementia with lewy bodies (DLB). Indeed, the mutation of the GBA gene responsible for a decrease in the activity of glucocerebrosidase is the most frequent known genetic risk factor in DLB. However, mutations of the GBA gene are known in another pathology, Gaucher disease, in which treatments have been developed.

The objective of this research is to determine if glucocerebrosidase activity is decreased in DLB. This hypothesis could open up a therapeutic perspective, with treatments already used in Gaucher disease.

Conditions

  • Dementia With Lewy Bodies

Interventions

DIAGNOSTIC_TEST

Glucocerebrosidase

Blood sample (10ml) for GCase activity

GENETIC

GBA gene

Blood sample (10ml) for variants or mutations of the GBA gene

DIAGNOSTIC_TEST

Macrophage biomarkers

Blood sample (20ml) for macrophage biomarkers

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-17
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304195 on ClinicalTrials.gov